Search
Disclaimer
Clicking the images or links will redirect you to a website hosted by BenchSci that provides third-party scientific content. Neither the content nor the BenchSci technology and processes for selection have been evaluated by us; we are providing them as-is and without warranty of any kind, including for use or application of the Thermo Fisher Scientific products presented.
Invitrogen
HHV-8 ORF74 Monoclonal Antibody (462510)
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promotions']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.viewpromo']}}
{{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.promocode']}}: {{promo.promoCode}} {{promo.promoTitle}} {{promo.promoDescription}}. {{$productOrderCtrl.translations['antibody.pdp.commerceCard.promotion.learnmore']}}
产品信息
MA5-61536
产品规格
种属反应
Virus
宿主/亚型
Mouse
/ IgG2b
分类
Monoclonal
类型
Antibody
克隆号
462510
抗原
NS0 mouse myeloma cell line transfected with viral HHV8-ORF74, Met1-Thr342
偶联物
形式
Lyophilized
浓度
0.5 mg/mL
纯化类型
Protein A/G
保存液
PBS with trehalose
内含物
no preservative
保存条件
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
运输条件
Ambient (domestic); Wet ice (international)
RRID
产品详细信息
Reconstitute at 0.5 mg/mL in sterile PBS.
靶标信息
HHV-8 ORF74 is a gene encoded by Human Herpesvirus 8 (HHV-8), also known as Kaposi's Sarcoma-associated Herpesvirus (KSHV). ORF74 is notable for encoding a G protein-coupled receptor (GPCR) known as vGPCR or KSHV-GPCR. This viral GPCR is homologous to human chemokine receptors and is constitutively active, meaning it can signal in the absence of ligand binding. The constitutive activity of ORF74 leads to the continuous activation of downstream signaling pathways, including those involving MAPK/ERK and NF-kappaB, which promote cell proliferation, survival, and angiogenesis. This activity is implicated in the pathogenesis of Kaposi's Sarcoma, as well as other HHV-8-associated diseases such as primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). The oncogenic potential of ORF74 makes it a significant target for research into therapeutic interventions aimed at treating HHV-8-related malignancies. Understanding the mechanisms by which ORF74 contributes to viral oncogenesis and immune evasion is critical for the development of targeted therapies that can mitigate the effects of this viral gene product.
仅用于科研。不用于诊断过程。未经明确授权不得转售。
篇参考文献 (0)
您是否在文献中引用过该产品？请点击下方按钮邮件告知我们。
